Indian Pharmaceutical Sector Poised for Sustained Double-Digit Growth, Equirus Reports
Financial analysts at Equirus project a continued upward trajectory for India's domestic drug market, driven by chronic care demand and strategic pricing adjustments.
Market Resilience and Growth Projections
The Indian pharmaceutical market (IPM) is demonstrating significant resilience, with financial services firm Equirus forecasting that the current momentum of double-digit growth is likely to persist through the coming fiscal cycles. This optimistic outlook follows a period of robust performance where domestic drug manufacturers successfully navigated global supply chain disruptions and inflationary pressures to maintain healthy margins.
According to the latest analysis, the primary catalysts for this expansion include a favorable product mix, consistent demand in the chronic therapy segment, and the ability of major players to implement strategic price increases within the regulatory frameworks established by the National Pharmaceutical Pricing Authority (NPPA).
Drivers of Domestic Demand
A pivotal factor in the sustained growth of the IPM is the shifting demographic and disease profile of the Indian population. There is an increasing prevalence of lifestyle-related ailments such as diabetes, cardiovascular diseases, and hypertension. These chronic conditions require long-term medication, providing a steady and predictable revenue stream for pharmaceutical companies.
Equirus notes that the chronic segment has consistently outpaced the acute segment in terms of growth rate. Furthermore, increased healthcare awareness and improved diagnostic capabilities across Tier-2 and Tier-3 cities are expanding the patient pool, allowing companies to penetrate deeper into previously underserved geographical markets.
Pricing Power and Regulatory Landscape
While the Indian market is known for its price sensitivity and stringent regulatory oversight, recent trends suggest that companies have successfully managed to pass on a portion of increased input costs to consumers. The annual revision of the Wholesale Price Index (WPI) allows for periodic adjustments in the prices of essential medicines under the National List of Essential Medicines (NLEM).
For non-scheduled formulations, companies have utilized the 10% annual price hike allowance to offset the rising costs of active pharmaceutical ingredients (APIs) and packaging materials. This pricing flexibility, combined with volume growth, has been instrumental in maintaining the double-digit value growth observed in recent quarters.
Strategic Shifting Toward Branded Generics
The report highlights a strategic pivot among leading Indian pharma entities toward high-margin branded generics. By investing in brand building and strengthening their field forces, companies are enhancing their medical representative (MR) productivity. This focus on branding helps in creating physician loyalty and allows for better differentiation in a crowded marketplace.
Digital transformation is also playing a role. From digital marketing to healthcare providers to the adoption of advanced analytics for supply chain management, technology is helping firms optimize their operational expenditures, thereby supporting the bottom line even as they pursue aggressive top-line targets.
Future Outlook and Risks
Looking ahead, Equirus remains bullish on the sector's ability to sustain this trajectory. The integration of specialty medicines and the potential for biosimilars in the domestic market represent the next frontier for growth. However, the report also cautions that any significant changes in government procurement policies or a widening of the price control umbrella could pose risks to future margins.
Despite these potential headwinds, the fundamental drivers—ranging from rising per capita healthcare expenditure to a robust pipeline of new launches—suggest that the Indian pharmaceutical market is well-positioned to remain a high-performing sector within the broader economy.